Curaleaf Q2 revenue down 8%
Overview
Curaleaf Q2 2025 revenue falls 8% yr/yr
Adjusted gross margin improves 120 basis points to 49% yr/yr
International revenue grows 62% yr/yr, driven by robust demand
Outlook
Company anticipates Turkey market launch in 2026
Company aims to capitalize on emerging cannabis opportunities
Result Drivers
DOMESTIC STABILIZATION - Curaleaf reports stabilization in domestic markets, contributing to sequential revenue growth
INTERNATIONAL MOMENTUM - International revenue grew 62% yr/yr, driven by strong demand and expansion efforts
EFFICIENCY IMPROVEMENTS - Adjusted gross margin increased 120 basis points due to improved cultivation and manufacturing efficiencies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Total Revenue | $315 mln | ||
Q2 Gross Profit | $152.55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Curaleaf Holdings Inc is C$4.00, about 34.8% above its August 5 closing price of C$2.61
Press Release:
